Princeton-based Soligenix Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced it appointed Jonathan Guarino as senior vice president and chief financial officer.
Karen Krumeich, who has served as senior vice president and chief financial officer since June 2016, will be pursuing new opportunities.
“We are delighted to welcome Jonathan to our team, as we leverage his combination of financial acumen and commercial and business experience,” stated Christopher Schaber, president and chief executive officer of Soligenix. “As we continue to execute our growth strategy, we are clearly building momentum toward potential commercialization and the talent we are attracting is an absolute reflection of our solid progress to date.”
“I am excited about Soligenix’s potential to become a commercial company and am thrilled to be joining the company at this pivotal time. I look forward to helping the company achieve success and create additional value,” said Guarino.
Guarino has more than 20 years of diverse experience in the financial and strategic management of emerging growth and commercial companies, including in the life sciences industry. He also has expertise in corporate financial operations, partnerships, as well as growth financings.
Guarino has experience with both development-stage and commercial companies. Most recently, he served as corporate controller for Hepion Pharmaceuticals Inc. (formerly ContraVir Pharmaceuticals Inc.), an Edison-based, public biotechnology company, where he contributed to the establishment of the financial infrastructure, as well as assisted with capital fund-raising and debt financings.
Previously, he worked as controller and senior manager of technical accounting for Suite K Value Added Services LLC and Covance Inc. Prior to these positions, he held accounting and finance positions of increasing importance with several companies, including PricewaterhouseCoopers LLP, BlackRock Inc. and Barnes & Noble Inc.